Business
Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipated in Q1 2022
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021\n Topline readout of Group 2 active disease anticipated in Q1 2022\n Company to host year-end conference call and webcast in Q1 2022\n\n\nHOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. \n\n \n \n \n \n \n \n\n \n\"This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leukemia, or AML,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"We are pleased to announce that the first patients in Marker's Phase 2 AML trial have been dosed with study drug. Further, we are on track to enroll the first 20 patients of the trial in the fourth quarter, with the first data readout expected in the first quarter of 2022. We look forward to providing year-end updates in a conference call and webcast early next year.\"\nPROGRAM UPDATES\nThe Company continues to enroll patients and activate clinical sites across the U.S. in Marker's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant AML. The trial is expected to enroll approximately 120 patients in the adjuvant setting and 40 patients with active disease at approximately 20 clinical sites.BUSINESS UPDATES\nThe Company's new cGMP manufacturing facility in Houston, Texas is fully operational and is supporting ongoing operations. The facility will also manufacture Marker's MultiTAA-specific T cell products for future hematological and solid tumor trials, in addition to producing the potential commercial supply of any products, if approved. In August, the Company announced that it received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company's Phase 2 AML trial. ANTICIPATED PROGRAM MILESTONES \nAML Trial Milestones\nEnrollment of first 20 patients of th...